The FDA has approved two new ready to use forms of glucagon and these have been introduced to the market: an intranasal powder (Baqsimi, Eli Lilly) and a stable liquid form without need for reconstitution (Gvoke, Xeris Pharmaceuticals). These innovative formulations provide the reliability of a ready-to-use glucagon preparation that can be administered quickly and simply.
